Duro-Tuss Expectorant

Quick links

Choose a section

Quick links to important sections

Advertisements

Duro-Tuss Expectorant

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Duro-Tuss Expectorant

Property Description
Active ingredient Bromhexine hydrochloride, Pholcodine
Form Oral solution (Syrup)
Pharmacological class Antitussive/Expectorant combination
Common use Relief of acute cough (wet and dry)
Origin Synthetic drug

Defining Duro-Tuss Expectorant: A Combination Antitussive/Expectorant

Duro-Tuss Expectorant is a distinct pharmaceutical preparation classified as an antitussive/expectorant combination drug, designed for systemic administration primarily through the oral route. It is provided as an oral solution, typically formulated as a syrup. This combination design is intended to address both mucus management and cough suppression in respiratory treatment.

As a combination drug, it incorporates two distinct synthetic drug compounds. Its high-level classification underscores its unique identity: it is formulated to combine the distinct therapeutic actions of a central cough suppressant with a mucolytic agent. This formulation is often marketed for adult and older patient groups, distinguishing its target audience from pediatric-only cough formulations.

Composition and Origin: The Dual Role of Bromhexine and Pholcodine

The medicine contains two principal active ingredients: Bromhexine hydrochloride and Pholcodine. Both are synthetic drug derivatives, ensuring precise chemical and pharmacological properties.

The components serve complementary roles: Bromhexine functions as a mucolytic agent and mucoregulatory agent, tasked with chemically breaking down and thinning thick respiratory secretions. Conversely, Pholcodine operates as a central cough suppressant and opioid derivative, targeting the cough reflex center in the brain to reduce the involuntary urge to cough. The use of Pholcodine targets persistent, non-productive coughing.

General Therapeutic Purpose for Acute Cough Symptoms

The general therapeutic purpose of this preparation is to provide relief for acute cough symptoms that involve both a persistent, irritating cough and the presence of cough with thick phlegm. This dual-action approach is utilized in scenarios where the cough disrupts rest and necessitates relief from both the excessive reflex and the underlying congestion.

By combining these distinct pharmacological actions, the medicine addresses the root cause (thick mucus) while simultaneously managing the cough reflex. This ensures a more manageable cough cycle, supporting overall recovery from respiratory congestion.

Regulatory References

  1. NIH StatPearls on Combination Cough Medications
  2. EMA Pholcodine withdrawal decision
Advertisements

What side effects are possible with Duro-Tuss Expectorant?

Possible Side Effects and Safety Information

Regulatory documents classify the potential adverse effects of this combination medicine (Bromhexine and Pholcodine) based on their frequency and the body system affected. These classifications structure the official understanding of the medicine's risk profile.


Frequency-Classified Adverse Reactions

The most Common adverse reactions documented include drowsiness, dizziness, nausea, vomiting, and constipation. These central nervous system (CNS) and gastrointestinal (GI) effects are reported more frequently, particularly at the start of treatment.

Uncommon reactions may include headache and certain hypersensitivity reactions. Reactions classified as Rare in regulatory labeling include more severe immune responses, such as anaphylactic reactions, angioedema, and bronchospasm.

Serious Adverse Reactions and Safety Constraints

Adverse effects considered serious and potentially life-threatening that are documented in official sources include Respiratory depression, which is a risk associated with the Pholcodine component. Furthermore, the development of severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), has been noted, with the highest risk window typically occurring during the first weeks of treatment.

Safety constraints noted in regulatory labeling include a contraindication for individuals with known hypersensitivity to the active ingredients. Specific caution is advised, and the product is generally contraindicated, in cases of severe hepatic impairment due to the potential for increased drug exposure. Older adults may be more susceptible to the common CNS effects, such as dizziness and drowsiness.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Overdose with this combination medicine primarily involves the risks associated with the Pholcodine component. Documented clinical manifestations of an overdose include drowsiness, nausea, vomiting, headache, and critically, respiratory depression. This overdose is classified in regulatory documents as capable of leading to severe poisoning and potential fatal overdose.


Immediate medical attention must be sought for any suspected overdose. Urgent hospital treatment is required due to the potential for severe, life-threatening outcomes. Contact with Poison Control Services is also mandated in the event of confirmed or suspected ingestion.


Regulatory management procedures specify that treatment is generally symptomatic and supportive. For cases of severe Pholcodine poisoning, the administration of the specific narcotic antagonist, Naloxone, may be indicated. Procedural measures such as stomach emptying via aspiration and lavage are also described in official guidance.


It is also documented that patients with severe hepatic or renal impairment may face increased severity risks. Furthermore, any sign of Severe Cutaneous Adverse Reactions (SCARs) or other severe allergic symptoms requires the immediate discontinuation of the medicine and urgent medical evaluation.

Advertisements

Therapeutic Uses of Duro-Tuss Expectorant

What Duro-Tuss Expectorant treats: main uses and benefits

This medication is generally used to provide symptomatic relief for acute cough that presents with a complex pattern, presenting with the simultaneous presence of a persistent, irritating cough and thick, viscous mucus. It helps manage symptoms related to both the unproductive urge and underlying chest congestion. The formulation is commonly applied in clinical settings involving conditions such as the common cold, influenza, and acute bronchitis. The medication is applied in therapeutic areas involving the symptomatic relief of cold and flu manifestations, including both dry cough and chest congestion. Products in this pharmacological class are designed to temporarily relieve these cold and flu symptoms, including both the dry cough and associated chest congestion.

A key therapeutic benefit is providing support that helps ease the overall symptom burden. The combination formula is relevant when the cough and congestion are active and interfering with daily comfort, which is particularly true when the cough severely disrupts rest for adults and older patient groups.


Quick Fact: Relief for Dual Symptoms

The medication helps address groups of symptoms that may appear suddenly or intensify over time, providing support that assists with relief of chest congestion and may help manage the discomfort of a sustained cough.

Regulatory References

  1. Health Canada Guidance on Oral Cough, Cold and Flu Labelling
Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Duro-Tuss Expectorant?

Population eligibility for this combination medicine, containing Pholcodine and Bromhexine, is strictly regulated and highly restricted.

Populations for whom use is Contraindicated:

  • Children under the age of 6 years (Absolute prohibition).
  • Patients with known hypersensitivity to pholcodine, bromhexine, or excipients.
  • Individuals with severe hepatic (liver) or renal (kidney) failure.
  • Patients taking Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of stopping such treatment.
  • Patients with acute asthma attacks, risk of respiratory failure, COPD, or chronic bronchitis.

Eligibility Status

Age Group / Condition Regulatory Classification
Adults and Adolescents (12+ years) Allowed under standard labeled conditions.
Children 6–11 years Restricted use (requires professional consultation).
Pregnancy and Lactation Not Recommended (Use is conditional only if essential).
Prior Pholcodine Use (12 months) Severe Restriction (Risk factor for anaphylaxis with certain anaesthetics, leading to withdrawal in some countries).
Advertisements

What should I know about interactions with other medicines?

The official regulatory profile for this combination medicine establishes specific interaction patterns and mandatory restrictions based primarily on the action of its active component, Pholcodine.

Contraindicated Combinations and Timing Restrictions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated and prohibited. This restriction extends to a mandatory separation time: the medicine must not be used for 14 days after stopping MAOI treatment.

Pharmacodynamic and Hypersensitivity Interactions

Due to its classification, the medicine may enhance the sedative effect of other CNS depressants, including alcohol, barbiturates, hypnotics, narcotic analgesics, and specific tranquillisers or antidepressants. This is a documented additive pharmacodynamic interaction.

Use with Antihypertensives or Diuretics may accentuate the hypotensive effects (low blood pressure). A key interaction-related constraint involves Neuromuscular Blocking Agents (NMBAs) used during general anaesthesia. Regulatory warnings identify prior use of this product as a risk factor for anaphylaxis when NMBAs are administered. This caution related to the hypersensitivity risk may apply for up to 12 months preceding the procedure.

Exposure and Metabolic Profile

Regarding the Bromhexine component, studies confirm its pharmacokinetics are not relevantly affected when co-administered with antibiotics such as Ampicillin, Oxytetracycline, or Erythromycin. Its potential for interaction with CYP450 2C9/3A4 substrates is formally stated as unlikely.

Advertisements

Mechanism of Action

How Duro-Tuss Expectorant Works: Mechanistic Domains


Modulation of Airway Secretion Fluidity

This mechanistic domain involves the Guaifenesin component, which acts via a reflex pathway originating in the stomach's vagal receptors. This pathway signals the bronchial glands to increase the output of low-viscosity, watery fluid. The resulting physiological effect is the hydration and dilution of thick mucus, resulting in a secretion volume with reduced concentration and lowered resistance to movement.

Direct Mucus Fiber Breakdown (Mucolysis)

This mechanism is driven by the Bromhexine component, which chemically targets the acidic mucopolysaccharide fibers that contribute to phlegm's high viscosity. By initiating the depolymerization of these sticky fibers, Bromhexine structurally reduces the adherence and thickness of the secretions. This transformation contributes to lowering the rheological barriers to clearance.

Synergistic Enhancement of Airway Clearance

The two mechanisms converge to enhance the mucociliary clearance pathway. The combination of dilution and chemical breakdown reduces the physical resistance encountered by the tiny cilia lining the airways. Bromhexine also provides a secretomotoric effect, modulating the ciliary transport efficiency, which supports the physical movement of the thinned material out of the respiratory tract.

Advertisements

Dosage and Administration Information

Official Administration of Duro-Tuss Expectorant

Duro-Tuss Expectorant, an oral solution containing Pholcodine and Bromhexine, is administered via the oral route as a liquid. The usage protocol involves the accurate measurement of the volume and adherence to defined time intervals.


Dosing Schedule and Frequency

Population Single Dose Range Maximum Daily Limit
Adults and Children ge 12 years 10 to 15 mL 4 doses (every 6 hours)
Children 6–11 years 5 to 10 mL 4 doses (every 6 hours)

This regimen establishes that the maximum total volume taken does not exceed four doses within any 24-hour cycle. The product is intended for short-term use for acute symptoms; it is typically used for no more than 5 days without consultation with a health professional.


Procedural Requirements

Proper use of the oral solution involves shaking the bottle thoroughly before use. The prescribed volume is measured using a calibrated milliliter measuring device to ensure dosage accuracy, as household spoons are unsuitable for precise liquid dosing. The medicine may be taken with or without food. Use is restricted by age, and the product is not administered to children under 6 years of age.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Duro-Tuss Expectorant

Evidence Base for Acute Cough Symptoms

The research landscape for this medication, which contains two active ingredients, has primarily been studied for its application in conditions characterized by acute or disruptive episodes of cough. The evidence base includes a mix of Randomized Controlled Trials (RCTs) and systematic reviews that have evaluated short-term changes in adults.

In these studies, researchers explored patient-reported outcomes describing perceived discomfort, including measurements of cough frequency and subjective severity. The research also included outcomes related to sputum characteristics, monitored in studies of similar medicines. Trials were designed to monitor responses during periods of increased symptom activity, providing information on outcomes describing episodic or acute changes.


Types of Studies Examining the Combination and Its Components

The scientific evidence available for the fixed-dose combination often relies on studies of the individual active ingredients—Pholcodine and Bromhexine—rather than modern research on the specific combination formula. Data for the Pholcodine component often originate from older studies that examined short-term symptom patterns. Comparative evidence is lacking for the specific utility of combining these two components over using either component alone in large, contemporary trials.


Focus on Short-Term Outcomes and Measurement

Research typically involves follow-up durations that were limited, often lasting only a few days, aligning with the self-limiting nature of an acute cough. Findings describe patterns observed over these brief time intervals, but it is often challenging to distinguish observed patterns from the expected natural recovery. The studies thus provide research insights into short-term changes, but do not necessarily reflect full certainty about the product's role.


Studies in Older Adults and Other Sub-Populations

The available data primarily focuses on the general adult population. Data for certain groups remain insufficient, meaning the research provides limited information on outcomes for special populations, such as older adults or individuals with specific chronic health conditions (comorbidities). The results apply only to the populations studied.


Key Evidence Gaps and Scientific Uncertainty

Several factors contribute to scientific uncertainty. The evidence quality varies across studies, and many involve sample sizes that were modest in number. A key gap is the absence of large-scale clinical trials that directly examine the fixed-dose combination against a placebo. Overall, the research contributes to the broader evidence landscape but also indicates that certainty remains low for the patterns observed in the studies, and that the available data are still emerging.

Key Studies & References

  1. Safety withdrawal of pholcodine-containing cough and cold medicines (MHRA Regulatory Action)
  2. Cough (acute): antimicrobial prescribing (NICE guideline NG120)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Duro-Tuss Expectorant (FAQ)


Q: What is the main difference between an 'expectorant' like this and a cough suppressant?

Regulatory documents classify this medicine as a combination product because it addresses two distinct issues. An expectorant (like Bromhexine) works to help thin and clear mucus from the airways, making the cough more productive. A central cough suppressant (like Pholcodine) works by acting on the cough reflex center in the brain to reduce the involuntary urge to cough.


Q: Does Duro-Tuss Expectorant make you drowsy or sleepy?

Yes, official labeling lists drowsiness and dizziness as common adverse reactions. These effects are observed more frequently, especially at the start of treatment, due to the central action of the Pholcodine component.


Q: Is it safe to drive after taking Duro-Tuss Expectorant?

Due to the potential for dizziness and drowsiness, regulatory documents advise caution regarding activities like driving or operating machinery. This caution should be applied until the user is certain how the medicine affects them.


Q: Does alcohol interact with Duro-Tuss Expectorant?

Yes, official product information indicates that co-administration with alcohol may enhance the sedative effects of the central nervous system depressants in the medicine. This additive effect is documented in the product's official interaction profile.


Q: Can Duro-Tuss Expectorant cause stomach upset?

The official regulatory label lists gastrointestinal effects as common adverse reactions. These effects include nausea, vomiting, and constipation.


Q: Can you use Duro-Tuss Expectorant if you are pregnant or breastfeeding?

Regulatory documents state that use during pregnancy and lactation is generally not recommended. Official documents describe the use as conditional, meaning it is not recommended unless deemed essential by a healthcare professional.


Q: I am taking medication for depression; is it safe to use Duro-Tuss Expectorant?

The medicine is strictly contraindicated if a patient is currently taking Monoamine Oxidase Inhibitors (MAOIs) or has stopped taking them within the last 14 days. Regulatory warnings highlight the potential for enhanced sedative effects when used with certain other antidepressants.


Q: Does Duro-Tuss Expectorant interact with pain relievers like paracetamol or ibuprofen?

Regulatory documents primarily focus on interactions with CNS depressants. While the Bromhexine component is not known to have major interactions, the Pholcodine component may potentially affect the excretion rate of other drugs. This detail would be described in the full list of interactions in the product information.


Q: What happens if you accidentally take more than the suggested amount?

Taking more than the suggested amount is considered an overdose, and regulatory documents list potential symptoms. These may include intensified effects such as drowsiness, dizziness, lack of coordination (ataxia), and potentially serious issues like respiratory depression.


Q: I've heard people call this a 'cough syrup' - is that the only form it comes in?

Official documentation classifies this product as an oral solution. This liquid preparation is commonly formulated as a syrup for ease of administration.


Q: Is it normal to feel a bit nauseous after taking Duro-Tuss Expectorant?

Regulatory labeling lists nausea and vomiting among the common adverse reactions. This classification means these symptoms are frequently observed, particularly when treatment is initiated.


Q: Why does the label mention not using it for long periods of time?

This medication is strictly for short-term use to manage acute symptoms. Prolonged use is advised against because a persistent cough may signal a serious underlying medical condition that requires investigation. Additionally, some regulatory warnings relate prior long-term use to hypersensitivity risks during general anesthesia.


Q: Are there different versions of Duro-Tuss Expectorant for night-time versus day-time?

The specific combination product containing Pholcodine and Bromhexine has a component with sedative potential. This makes the formulation a key safety consideration for the timing of its use, especially when alertness is required.


Q: Can people with diabetes use Duro-Tuss Expectorant?

The suitability for people with diabetes depends entirely on the specific product formulation. Some versions of this medication are specifically formulated to be sugar-free and may be suitable. The suitability is determined by reviewing the inactive ingredients listed on the product label.


Q: Are there any sweeteners or colors in the syrup version?

The presence of sweeteners or colors is dependent on the specific product formulation. The full list of inactive ingredients, or excipients, is contained within the product information leaflet.


Q: How long after the expiry date is Duro-Tuss Expectorant safe to use?

Regulatory guidelines are clear that the product must not be used after the expiry date printed on the packaging. The medicine's stability, quality, and effectiveness are only guaranteed up to that specified date.


Q: Can I use Duro-Tuss Expectorant if I have asthma?

The product is contraindicated—meaning its use is prohibited—in patients experiencing an acute asthma attack. If there is a history of asthma, caution is advised when using it. The full contraindications are described in the official documentation.


Q: Is the active ingredient similar to what is in Mucinex?

The main active expectorant in this product is Bromhexine, which works to thin mucus. This is chemically different from Guaifenesin, which is the active expectorant found in many Mucinex products. Both ingredients are generally classified as agents that help with mucus clearance.


Q: Are there any official warnings about allergic reactions?

Yes, official documents list allergic reactions, including severe ones like anaphylaxis (a serious, whole-body allergic reaction), as rare but documented adverse effects. There are also specific regulatory warnings concerning the risk of a reaction with certain general anesthetics following prior use of this product.


Q: Does the medicine come in a sugar-free formulation?

The availability of a sugar-free formulation depends on the specific version of the product on the market. This detail is specified on the product label.


Q: Why is it important to store the medicine out of reach of children?

Storage instructions explicitly require the medicine to be kept out of reach of children to prevent accidental ingestion. Due to the potent central action of the active ingredients, accidental overdose in children carries a high risk of serious adverse reactions.


Q: Do regulatory bodies classify this drug as generally safe for short-term use?

Yes, regulatory bodies have authorized and regulated this product for the short-term relief of acute cough symptoms. This approval is conditional on strict observance of all contraindications and special warnings detailed in the official product information.


Q: Can people with diabetes use Duro-Tuss Expectorant?

The suitability for people with diabetes is dependent on the specific product formulation. Some versions are explicitly labeled as sugar-free and may be appropriate. The suitability is determined by checking the inactive ingredients listed on the product label.


Q: Are there any reports of long-term side effects from using this medicine?

The medicine is authorized only for short-term use. The official safety profile and documentation are based on data from acute, short-term use. Information on potential long-term side effects is generally not available, and prolonged use is advised against.


Q: Does Duro-Tuss Expectorant affect my ability to operate machinery?

Yes, official product information advises caution regarding the operation of machinery or vehicles. This is due to the potential for the medicine to cause dizziness and drowsiness.


Q: What is the reason for the age restriction on this medicine?

Use is strictly prohibited for children under the age of 6 years. This restriction is primarily due to the potential for serious adverse reactions, notably the risk of respiratory depression, which is associated with the central cough suppressant component (Pholcodine).


Q: What are the most commonly reported side effects in studies or official documents?

Based on official documents, the most commonly reported adverse reactions include effects such as drowsiness, dizziness, nausea, vomiting, and constipation.


Q: Does taking more water help the expectorant work better?

The expectorant component works to thin mucus and clear congestion. Regulatory information for similar medicines often includes the principle that drinking plenty of fluids can help thin respiratory secretions and assist with clearance.


Q: Why is it important to check with a doctor if the cough lasts longer than a week?

Official warnings state that this medicine is for acute use only. A cough that persists for more than a few days may be a sign of a serious underlying condition that requires medical investigation and cannot be treated solely with over-the-counter medicine.


Q: Is this medicine gluten-free or suitable for people with celiac disease?

The suitability for individuals requiring a gluten-free diet is dependent on the specific formulation. The presence of gluten can be determined by reviewing the list of excipients (inactive ingredients) on the product label for the specific version being used.

Advertisements

How should Duro-Tuss Expectorant be stored and disposed of?

How to Store and Dispose of Duro-Tuss Expectorant

Storage of the oral solution must adhere to specific regulatory requirements to maintain product stability and ensure safety.

Storage Requirements

  • Temperature and Environment: Store the medicine in a cool, dry place at or below 30 C. Do not refrigerate the liquid formulation or store it in prohibited environments like the bathroom, near a sink, on a window sill, or in a car.
  • Container and Stability: Keep the medicine in its original pack. Do not use the product if the packaging seal is broken or if it is past the expiry date.
  • Child Protection: The product must be stored where children cannot reach it. This typically requires placing the medicine in a locked cupboard at least 1.5 metres above the ground.

Disposal Instructions

Expired or unused Duro-Tuss Expectorant must be handled as pharmaceutical waste. Return any expired or unused medicine to your pharmacist for disposal; do not discard it in household trash or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Duro-Tuss Expectorant found in:

A-Z Index: